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Abstract
Background: In the medical literature, the nomenclature and descriptions (ND) of small bowel (SB) ulcerative and inflam-
matory (U-I) lesions in capsule endoscopy (CE) are scarce and inconsistent. Inter-observer variability in interpreting these
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findings remains a major limitation in the assessment of the severity of mucosal lesions, which can impact negatively on
clinical care, training and research on SB-CE.
Objective: Focusing on SB-CE in Crohn’s disease (CD), our aim is to establish a consensus on the ND of U-I lesions.
Methods: An international panel of experienced SB-CE readers was formed during the 2016 United European
Gastroenterology Week meeting. A core group of five CE and inflammatory bowel disease (IBD) experts established an
Internet-based, three-round Delphi consensus but did not participate in the voting process. The core group built illustrated
questionnaires, including SB-CE still frames of U-I lesions from patients with documented CD. Twenty-seven other experts
were asked to rate and comment on the different proposals for the ND of the most frequent SB U-I lesions. For each round,
we used a 6-point rating scale (varying from ‘strongly disagree’ to ‘strongly agree’). The consensus was reached when at
least 80% of the voting members scored the statement within the ‘agree’ or ‘strongly agree’ categories.
Results: A 100% participation rate was obtained for all the rounds. Consensual ND were reached for the following seven U-I
lesions: aphthoid erosion, deep ulceration, superficial ulceration, stenosis, edema, hyperemia and denudation.
Conclusion: Considering the most frequent SB U-I lesions seen in CE in CD, a consensual ND was reached by the inter-
national group of experts. These descriptions and names are useful not only for daily practice and medical education, but
also for medical research.
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Introduction
Considering its high ability to visualise the entire small
bowel (SB) mucosa, capsule endoscopy (CE) has rapidly
been considered as one of the first-line diagnostic tools
for SB examination.1 CE has an approximate diagnostic
yield of 50% in suspected Crohn’s disease (CD) cases2
and plays a significant role in its management.3,4 The
Capsule Endoscopy Crohn’s Disease Activity Index
(CECDAI) was developed5 and validated6 to grade the
severity of SB-CE findings in patients with CD. The
Lewis score also provides a common language to quan-
tify mucosal inflammatory variations.7 Both scores are
commonly used both in clinical practice and in research
because they display a strong correlation.8 However, the
nomenclature and descriptions (ND) of ulcerative and
inflammatory (U-I) lesions seen in CE and that are
used in these scores are far from established. For
instance, in the study by Gralnek et al., the ‘definitions
of endoscopic lesions were a priori specified and
reviewed by all readers prior to prospective testing’,
yet no definitions were consensually agreed and pro-
vided.7 As CE reviewing is strongly related to the read-
er’s opinion and experience, which differ among
readers,9,10 it is crucial to search for a common inter-
national ND to define the most common U-I lesions
seen on SB-CE in patients with CD.
Indeed, in the medical literature, studies assessing the
inter-observer variability have measured a mean kappa
value of around 0.5.11 We believe that the inter-observer
variability in interpreting the findings may be (at least
partly) due to the lack of a common language, and that it
is a major limitation for assessing the severity of muco-
sal lesions observed in inflammatory bowel diseases
(IBD), with a potential negative impact on patients’
healthcare and on the evaluation of therapeutics.
Therefore, it seems necessary to standardise and use a
unified language for all major U-I lesions seen during
SB-CE in IBD. A similar approach has been used by our
group through the establishment of an international
consensus on the ND of the most frequent vascular
lesions seen in SB-CE.12 Hence, the aim of the current
study was to establish a consensual ND of the most
commonU-I lesions seen on SB-CE in patients with CD.
Patients, materials and methods
Design
The Delphi method is one of the most accurate and
validated process for answering questions that cause
uncertainty even among experts.13,14 The present study
used a Delphi consensus model based on alternative
feedback rounds between a core group (CG) and an
expert group (EG) until a consensus was reached
(Figure 1). The CG built several Internet-based illu-
strated questionnaires and asked the EG to rate the
descriptions and add comments to inform the next
round. The questionnaires were structured similarly,
presenting images related to several propositions for
the nomenclature and the semantic descriptions of U-I
lesions seen in CD patients. All members of the EG were
invited to add comments for each proposal. Based on
the rating and on the comments received from the
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experts, the name and the description of each lesion were
then reviewed by the CG after each feedback round.
Working groups and feedback rounds
The working groups were constituted during the 24th
United European Gastroenterology Week (15–19
October 2016, Vienna, Austria). The CG was composed
of five French IBD specialists, with three of them also
being SB-CE expert readers. The CG members did
not participate in the EG. The 27 members of the
international EG were based in England (n¼ 2),
France (n¼ 3), Germany (n¼ 1), Greece (n¼ 1),
Ireland (n¼ 1), Israel (n¼ 3), Italy (n¼ 5), Malta
(n¼ 1), the Netherlands (n¼ 1), Portugal (n¼ 1),
Scotland (n¼ 3), Spain (n¼ 2) and Sweden (n¼ 3).
The mean age of the EG members was 47.6 years.
The mean CE reading experience of the EG members
was 12.4 4.6 years, with a mean number of 136 85
CEs read annually.
Proposals and revisions of nomenclature and
semantic descriptions
To design the first round, the CG first reviewed relevant
U-I terms described in the SB-CE IBD scores5,7 or in
the papers of the digestive endoscopic terminology.15–17
Moreover, to avoid confusion, the CG also considered
the terms and definitions of U-I lesions found during
colonoscopy of IBD patients, as proposed by Groupe
d’Etudes The´rapeutiques des Affections Inflammatoires
du Tube Digestif (GETAID).18
The CG proposed a selection of four typical SB-CE
image frames, a nomenclature and a semantic
Post Round 1 analysis 
Core group (n=5) 
Consensual nomenclature and descriptions 
of most common SB ulcero-inflammatory lesions seen in CE
Post Round 3 analysis
Core group (n =5)
Post Round 2 analysis
Core group (n =5)
Round 3 Experts group (n=27)
Round 2 Experts group (n=27)
Round 1 Experts group (n =27)
First set of proposals for nomenclature and descriptions 
of SB ulcero-inflammatory lesions    
Core group (n=5)
Selection of the most common ulcero-inflammatory images seen in SB-CE*, based on validated scores 
Selection of 4 typical frames for each type of lesion, from the CAD-CAP** database 
Delphi consensus group establishment
Core group (n = 5)            Experts group (n = 27)
Figure 1. Delphi consensus study flowchart. *SB-CE: small bowel capsule endoscopy. **CAD-CAP: Computer-aided Diagnosis for capsule
endoscopy database (19).
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description per specific type of SB U-I lesion. All
selected frames were extracted from the multicentre
French database CAD-CAP (computer-assisted diag-
nosis for capsule endoscopy). This database is com-
posed of 20,000 normal CE still frames and 5184 still-
frame images of abnormal CE findings from third-gen-
eration SB-CE system videos (PillcamSB3 system,
Medtronic), including 1369 images with U-I lesions
from patients with IBD.19 It has already been used to
standardise and illustrate a common lexicon for vascu-
lar lesions seen in SB-CE12 and to develop CAD tools
for capsule reading.20 An Internet-based survey was
used to send all the propositions to the EG.
For each round, the EG members were invited to
rate the propositions made for each type of lesion,
using a numerical scale varying from 1 (strongly dis-
agree) to 6 (strongly agree) (Table 1). They were also
asked to provide comments and suggestions for subse-
quent revisions. To improve the lesions ND, the CG
reviewed the EG’s suggestions after each round.
Predefined stop criterion and analysis
We considered a consensual agreement was reached
when over 80% of the voting members rated with a
score of 5 (agree) or 6 (strongly agree) within three
rounds. The Delphi consensus process was stopped
when the consensual name and description of any
lesion was established. Meetings were organised
between the five participants of the CG within the
first three rounds to discuss the votes and comments.
Subsequently, whether a consensus was reached or not,
the process was interrupted.
Results
The CG identified the seven following lesions to be
proposed to the EG for definition and description:
aphthoid erosion, deep ulceration, superficial ulcer-
ation, stenosis, edema, denudation and hyperemia. A
100% participation rate was obtained from the EG for
all three rounds. The consensual ND, as finally
obtained at the end of the Delphi process, are given
in Table 2. The experts’ ratings are detailed in Tables
3 and 4 for the nomenclature and descriptions,
respectively.
Aphthoid erosion
Regarding Figure 2(a), the nomenclature voted on for
this type of lesion after one round with an 85.2% agree-
ment rate was ‘aphthoid erosion’. After round 2, the
description ‘Diminutive loss of epithelial layering with
a whitish centre and a red halo, surrounded by normal
mucosa’ obtained a 96.3% agreement rate.
Deep ulceration
Regarding Figure 2(b), the nomenclature ‘deep ulcer-
ation’ was voted on for this type of lesion after one
round with a 96.3% rate of agreement. The description
‘Frankly, deep loss of tissue compared with the sur-
rounding swollen/edematous mucosa, with a whitish
base’ reached an 85.2% rate of agreement after
round 3.
Superficial ulceration
Regarding Figure 2(c), the nomenclature ‘superficial
ulceration’ was voted on for this type of lesion after
one round with an 81.5% rate of agreement. The rate
of agreement for the description ‘Mildly depressed loss
of tissue with a whitish bottom, whose features fit neither
with that of aphthoid erosion nor with that of deep
ulceration, as previously defined’ was of 85.2% after
round 2. Although referring to the descriptions of
‘deep ulceration’ and ‘aphthoid erosion’, a consensual
description for ‘superficial ulceration’ was obtained
before this, during round 2.
Stenosis
Regarding Figure 3(a), after one round the nomencla-
ture ‘stenosis’ was voted on for this type of lesion with a
100.0% rate of agreement. During round 1 the EG
asked for videos to further discuss the description. A
9-second video sequence (25 frames upstream, and 25
downstream the index still frame) was added to the
questionnaire during round 2, as well as a special men-
tion for the need of a dynamic sequence to establish a
diagnosis. After round 2, the rate of agreement of the
following description: ‘Narrowing of the intestinal
lumen withholding or delaying the passing of the video-
capsule (therefore, to be evaluated on a video)’ was of
88.9%.
Edema
After round 1, the EG asked for modifications in the
selection of the SB-CE illustrations. Regarding
Table 1. Six-point numerical scale to rate proposals during the
Delphi rounds.
1 Strongly disagree
2 Disagree
3 Moderately disagree
4 Moderately agree
5 Agree
6 Strongly agree
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Figure 3(b), the nomenclature voted on for this type of
lesion after two rounds was an ‘edema’ with an 85.2%
rate of agreement. A rate of agreement of 81.5% was
reached after round 2 for the following description:
‘Enlarged/swollen/engorged villi’.
Hyperemia
A hyperemia is a nonspecific finding often associated
with other common U-I lesions. During the first two
rounds the EG asked the CG for modifications in the
selection of the SB-CE images. Thus, two frames were
Table 2. International Delphi consensus on the nomenclature and descriptions of ulcerative and inflammatory lesions in SB-CE.
Nomenclature Description
% Nomenclature/
description
Aphthoid erosion Diminutive loss of epithelial layering with a whitish center and a red halo,
surrounded by normal mucosa
85.2/96.3
Deep ulceration Frankly deep loss of tissue compared to the surrounding swollen/edematous
mucosa, with a whitish base
96.3/85.2
Superficial ulceration Mildly depressed loss of tissue with a whitish bottom, whose features fit neither
with that of aphthoid erosion nor with that of deep ulceration, as previously defined
81.5/85.2
Stenosis Narrowing of the intestinal lumen withholding or delaying the passing of the
videocapsule (therefore, to be evaluated on a video)
100.0/88.9
Edema Enlarged / swollen / engorged villi 85.2/81.5
Hyperemia Area of reddish villi 96.3/81.5
Denudation Reddish (but not whitish) mucosal area where villi are absent 81.5/81.5
Table 4. Experts’ rating on the description of the selected ulcerative and inflammatory SB lesions.
Description
Numerical scale / Number of expert voting
1 2 3 4 5 6
% of ‘agree’ or
‘strongly agree’
Number of
rounds passed
Aphthoid erosion – – – 1 13 13 96.3 2
Deep ulceration – 1 – 3 14 9 85.2 3
Superficial ulceration – – – 4 15 8 85.2 2
Stenosis – – 1 2 13 11 88.9 2
Edema – 1 – 4 14 8 81.5 2
Hyperemia 1 1 3 14 8 81.5 3
Denudation – 1 – 4 10 12 81.5 1
Table 3. Experts’ rating regarding the nomenclature of the selected ulcerative and inflammatory SB lesions.
Nomenclature
Numerical scale / Number of expert voting
1 2 3 4 5 6
% of ‘agree’ or
‘strongly agree’
Number of
rounds passed
Aphthoid erosion 2 – 2 – 12 11 85.2 1
Deep ulceration 1 – – – 5 21 96.3 1
Superficial ulceration – – 2 3 11 11 81.5 1
Stenosis – – – – 9 18 100.0 1
Edema – 1 1 2 12 11 85.2 2
Hyperemia – – 1 – 21 6 96.3 3
Denudation – 1 – 4 10 12 81.5 1
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removed from the initial selection. The regions of inter-
est within the two remaining frames were delimited
(Figure 3(d)). The nomenclature voted on for
Figure 3(d) after three rounds was a ‘hyperemia’ with
a 96.3% rate of agreement. An 81.5% rate of agree-
ment was reached after round 3 for the description:
‘Area of reddish villi’.
Denudation
Regarding Figure 3(c), an 81.5% rate of agreement was
reached for the nomenclature ‘denudation’ after one
round. After round 1 the following description:
‘Reddish (but not whitish) mucosal area where villi
are absent’ obtained an 81.5% rate of agreement.
Discussion
In the current study, the ND of seven common
U-I lesions seen in SB-CE in IBD patients were
validated by experts who reached a more than 80%
consensus rate. The agreements were reached using a
Delphi consensus process conducted with 27 expert CE
readers.
Since its clinical inception in 2000, CE has revolu-
tionised the examination and description of the SB.
Figure 2. Frames with various types of loss of tissue. (a) Four typical frames of ‘Aphthoid erosion’; (b) Four typical frames of ‘Deep
ulceration’; (c) Four typical frames of ‘Superficial ulceration’.
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Although a terminology index exists for SB-CE,15 a
consensual ND of SB findings has not been clearly
established. This lack of ND makes it difficult to stand-
ardise SB-CE reading, reporting and research. Indeed,
in most studies evaluating the inter-observer agreement
in the description of SB-CE, only the experts’ opinions
are considered as the gold standard.
In an attempt to standardise the practice in SB-CE
reading, our group first performed a Delphi consensus
to better define and describe vascular lesions found in
SB-CE.12 Similarly, we propose in the present study a
consensus on the ND of U-I lesions seen in SB-CE in
IBD patients. During the Delphi process, several
important points were raised by the EG discussed sub-
sequently by the CG. First, some U-I lesions are con-
sidered ‘nonspecific’, such as U-I lesions caused by the
use of nonsteroidal anti-inflammatory drugs, by CD, by
ischaemia or by other factors that cannot be easily or
Figure 3. Frames with stenosis and with various types of inflammatory, non-ulcerated, lesions.
(a) Four typical frames of ‘Stenosis’; (b) Four typical frames of ‘Edema’; (c) Four typical frames of ‘Denudation’; (d) Two typical frames of
‘Hyperemia’.
Leenhardt et al. 105
categorically distinguished. Second, in SB-CE, as there
is currently no available tool to precisely measure
lesions, we could only use adjectives of size (e.g.
‘diminutive’) to describe the lesions instead of standar-
dised units of measurement. Third, several types of U-I
lesions are often found together in the same SB-CE
frame, making it difficult to define their specific descrip-
tions and illustrations. As an example, a consensus on
the term ‘hyperemia’ could not be achieved within the
two first rounds as this finding is nonspecific and often
associated with other common U-I lesions. However,
this issue was solved by delineating the regions of inter-
est within the selected frames. Fourth, it is important to
emphasise the difficulties in clearly distinguishing a
superficial from a deep ulceration. Indeed, the evalu-
ation of the depth of loss of tissue remains subjective
and variable between experts, and a villous appearance
contiguous to a mucosal break should be considered to
appreciate and better characterise the entire lesion.
The present study has many strengths. First, the
questionnaires were richly illustrated with high-quality,
third-generation SB-CE images to better guide the
experts. When required by the EG, still frames could
be changed or delineated, and short video sequences
could be specifically linked to the still images (e.g.
when commenting on the term ‘stenosis’). Such comple-
mentary information was provided when needed to
increase the precision in the lesion to be described
and to ensure a high reliability in the votes. Second, a
substantial number of experts (n¼ 27) voted, they had a
significant experience (mean 12.4 years) and performed
a high volume (mean 136 cases per year) of SB-CE
readings. Third, a 100% participation rate was
obtained in all three rounds. Fourth, all the answers
were anonymous, which encouraged open critique,
while avoiding and preventing some experts from dom-
inating in the process. Fifth, based on the EG’s answers
and comments, the members of the CG wrote out pro-
posals and revisions, but they did not participate in
the vote.
Some limitations should be acknowledged. First,
almost all of the investigators were based in Europe.
However, the 27 EG members were from 13 different
countries, thus offering some meaningful diversity for
such a study. Conversely, the five members of the CG
were all affiliated with France, where the project was
initiated, but they belonged to three different institu-
tions. Second, the selection of the seven types of lesions
to be studied was made by the CG based on their
experience and on a review of the literature that had
a special focus on the items of the CECDAI and the
Lewis score.5,7 The EG was not specifically asked
whether any other type of U-I lesion should be added
to the list and voted for. For the seven above-men-
tioned different types of lesions, however, the EG
members could comment and ask for modifications.
No EG expert requested adding an additional type of
U-I to the list. Third, all images have been captured
from the SB-CE Pillcam SB3 system only.
Therefore, it would be interesting to evaluate whether
the ND described here are relevant with other SB-CE
systems. Fourth, the current study represents a step
forward in the standardisation of the description of
CE lesions, and it does not assess the clinical relevance
of such lesions according to specific clinical settings.
Specifically, hyperemia and edema are subtle and
debatable lesions. Their consensual descriptions by
the experts were very short compared with that written
for other lesions. These brief descriptions may indeed
reflect the ideas of some IBD specialists that those find-
ings may not be true manifestations or markers of CD,
and that the validity of the Lewis Score is questionable
for that reason.21 Fifth, the current study aimed to pre-
cisely describe lesions, but there is currently no avail-
able measurement tool in SB-CE, and no possibility to
sample the lesions. Descriptive terms with adjectives
(e.g. ‘whitish/yellowish bottom’, ‘narrowing’) rather
than objective measurements (e.g. diameter, depth in
mm . . .) or pathology terms (e.g. fibrin bottom . . .)
were therefore used by both the CG and the EG.
Timing was nevertheless available, and should have
been quantified to precisely describe what the experts
call ‘withholding or delaying the passing of the video-
capsule’ when describing a stenosis. All in all, these
descriptions may change when the SB-CE technology
evolves and when readers call for even more precise and
reproducible reports.
The proposed nomenclatures, atlas and descriptions
of vascular and U-I lesions in SB-CE by our group pave
to way to a study assessing their intra- and inter-obser-
ver reproducibility. We also plan to conduct survey on
their clinical pertinence for the main indications of SB-
CE (occult or overt gastrointestinal bleeding, and sus-
picion of CD).
Conclusion
An international group of SB-CE expert readers
reached a consensus for the ND of the most frequent
U-I lesions seen in CE. The current study has provided
a strong asset for higher quality SB-CE reading and
reporting in patients with CD. These names and
descriptions will also be useful for medical education
and for medical research purposes.
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